Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 7, Status: Authorised
Orphan designation: Enzastaurin hydrochloride Treatment of glioma, 27/05/2024 Withdrawn
Agenda - ACT EU multi-stakeholder platform annual meeting
Union procedure on the coordination of veterinary pharmacovigilance inspections
Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections
Union procedure on the coordination of veterinary pharmacovigilance inspections
Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections
Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, Date of authorisation: 01/03/2004, Revision: 57, Status: Authorised
Human medicines European public assessment report (EPAR): Mevlyq, eribulin, Date of authorisation: 09/02/2024, Revision: 1, Status: Authorised
Quarterly System Demo - Q3 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 September 2024, 09:00 (CEST) to 18 September 2024, 13:15 (CEST)